Trial Profile
Phase II study of alternate-day administrations of S-1 as 2nd-line treatment in patients with metastatic and locally advanced pancreatic cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 16 Oct 2019
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Pancreatic cancer; Squamous cell cancer
- Focus Therapeutic Use
- 14 Oct 2019 Status changed from recruiting to discontinued.
- 16 May 2016 New trial record